Pharmacological Characterization, Structural Studies, and In Vivo Activities of Anti-Chagas Disease Lead Compounds Derived from Tipifarnib

Chagas disease, caused by the protozoan pathogen Trypanosoma cruzi, remains a challenging infection due to the unavailability of safe and efficacious drugs. Inhibitors of the trypanosome sterol 14α-demethylase enzyme (CYP51), including azole antifungal drugs, are promising candidates for development...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Buckner, Frederick S., Bahia, Maria Terezinha, Suryadevara, Praveen Kumar, White, Karen L., Shackleford, David M., Chennamaneni, Naveen Kumar, Hulverson, Matthew A., Laydbak, Joy U., Chatelain, Eric, Scandale, Ivan, Verlinde, Christophe L. M. J., Charman, Susan A., Lepesheva, Galina I., Gelb, Michael H.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2012
Assuntos:
Experimental Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3421879/
https://ncbi.nlm.nih.gov/pubmed/22777048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.06244-11
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados